These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 24721998)

  • 61. Prevalence of HIV, sexually transmitted infections, and viral hepatitis by Urbanicity, among men who have sex with men, injection drug users, and heterosexuals in the United States.
    Oster AM; Sternberg M; Nebenzahl S; Broz D; Xu F; Hariri S; Miles I; Paz-Bailey G
    Sex Transm Dis; 2014 Apr; 41(4):272-9. PubMed ID: 24622641
    [TBL] [Abstract][Full Text] [Related]  

  • 62. HIV-1 genetic diversity and transmitted drug resistance frequency among Iranian treatment-naive, sexually infected individuals.
    Vahabpour R; Bokharaei-Salim F; Kalantari S; Garshasbi S; Monavari SH; Esghaei M; Memarnejadian A; Fakhim A; Keyvani H
    Arch Virol; 2017 Jun; 162(6):1477-1485. PubMed ID: 28181034
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Transmitted drug resistance in newly diagnosed and treatment-naïve HIV type 1-infected patients in Hungary.
    Áy É; Müller V; Mezei M; Pocskay Á; Koroknai A; Müller D; Győri Z; Marschalkó M; Tóth B; Kárpáti S; Lakatos B; Szlávik J; Takács M; Minárovits J
    J Glob Antimicrob Resist; 2020 Mar; 20():124-130. PubMed ID: 31330377
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Development of an HIV Testing Dashboard to Complement the HIV Care Continuum Among MSM, PWID, and Heterosexuals in Washington, DC, 2007-2015.
    Patrick R; Greenberg A; Magnus M; Opoku J; Kharfen M; Kuo I
    J Acquir Immune Defic Syndr; 2017 Jul; 75 Suppl 3(Suppl 3):S397-S407. PubMed ID: 28604445
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Superimposing incident sexually transmitted infections on HIV phylogram to investigate possible misclassification of men who have sex with men as heterosexuals in a cohort in Antwerp, Belgium.
    Osbak KK; Meehan CJ; G Ribas S; Heyndrickx L; Ariën KK; Tsoumanis A; Florence E; Esbroeck MV; Fransen K; Kenyon CR
    Int J STD AIDS; 2019 Apr; 30(5):486-495. PubMed ID: 30999835
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Time trends in primary HIV-1 drug resistance among recently infected persons.
    Grant RM; Hecht FM; Warmerdam M; Liu L; Liegler T; Petropoulos CJ; Hellmann NS; Chesney M; Busch MP; Kahn JO
    JAMA; 2002 Jul; 288(2):181-8. PubMed ID: 12095382
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Trends in drug resistance prevalence in HIV-1-infected children in Madrid: 1993 to 2010 analysis.
    de Mulder M; Yebra G; Navas A; Martin L; de Jose MI; Navarro ML; de Ory SJ; Gonzalez-Granado I; Mellado MJ; Ramos JT; Holguin A
    Pediatr Infect Dis J; 2012 Nov; 31(11):e213-21. PubMed ID: 22785049
    [TBL] [Abstract][Full Text] [Related]  

  • 69. HIV-1 subtype B-infected MSM may have driven the spread of transmitted resistant strains in France in 2007-12: impact on susceptibility to first-line strategies.
    Frange P; Assoumou L; Descamps D; Chéret A; Goujard C; Tran L; Gousset M; Avettand-Fenoël V; Bocket L; Fafi-Kremer S; Guinard J; Morand-Joubert L; Nicot F; Plantier JC; Rogez S; Wirden M; Rouzioux C; Meyer L; Chaix ML; ;
    J Antimicrob Chemother; 2015 Jul; 70(7):2084-9. PubMed ID: 25885327
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Low prevalence of transmitted drug resistance in patients newly diagnosed with HIV-1 infection in Sweden 2003-2010.
    Karlsson A; Björkman P; Bratt G; Ekvall H; Gisslén M; Sönnerborg A; Mild M; Albert J
    PLoS One; 2012; 7(3):e33484. PubMed ID: 22448246
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Trends in Drug Resistance Prevalence, HIV-1 Variants and Clinical Status in HIV-1-infected Pediatric Population in Madrid: 1993 to 2015 Analysis.
    Rojas Sánchez P; Domínguez S; Jiménez De Ory S; Prieto L; Rojo P; Mellado P; Navarro M; Delgado R; Ramos JT; Holguín Á;
    Pediatr Infect Dis J; 2018 Mar; 37(3):e48-e57. PubMed ID: 28991889
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Molecular Epidemiology of HIV-1 in Eastern Europe and Russia.
    van de Klundert MAA; Antonova A; Di Teodoro G; Ceña Diez R; Chkhartishvili N; Heger E; Kuznetsova A; Lebedev A; Narayanan A; Ozhmegova E; Pronin A; Shemshura A; Tumanov A; Pfeifer N; Kaiser R; Saladini F; Zazzi M; Incardona F; Bobkova M; Sönnerborg A
    Viruses; 2022 Sep; 14(10):. PubMed ID: 36298654
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Long-lasting protection of activity of nucleoside reverse transcriptase inhibitors and protease inhibitors (PIs) by boosted PI containing regimens.
    Scherrer AU; Böni J; Yerly S; Klimkait T; Aubert V; Furrer H; Calmy A; Cavassini M; Elzi L; Vernazza PL; Bernasconi E; Ledergerber B; Günthard HF;
    PLoS One; 2012; 7(11):e50307. PubMed ID: 23189194
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Transmitted HIV-1 Drug Resistance in a Treatment-Naive Cohort of Recently Infected Individuals from Chennai, India.
    Nesakumar M; Haribabu H; Cheedarla N; Karunaianantham R; Kailasam N; Sathyamurthi P; Selvachithiram M; Tripathy SP; Hanna LE
    AIDS Res Hum Retroviruses; 2019 Aug; 35(8):775-779. PubMed ID: 31001987
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Drug resistance in B and non-B subtypes amongst subjects recently diagnosed as primary/recent or chronic HIV-infected over the period 2013-2016: Impact on susceptibility to first-line strategies including integrase strand-transfer inhibitors.
    Andreis S; Basso M; Scaggiante R; Cruciani M; Ferretto R; Manfrin V; Panese S; Rossi MC; Francavilla E; Boldrin C; Alvarez M; Dal Bello F; Mengoli C; Turriziani O; Sarmati L; Antonelli G; Andreoni M; Palù G; Parisi SG
    J Glob Antimicrob Resist; 2017 Sep; 10():106-112. PubMed ID: 28732792
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Trends in HIV testing, prevalence among first-time testers, and incidence in most-at-risk populations in Spain: the EPI-VIH Study, 2000 to 2009.
    Diez M; Bleda MJ; Varela JR; Ordonana J; Azpiri MA; Vall M; Santos C; Viloria L; de Armas C; Urena JM; Trullen J; Pueyo I; Martinez B; Puerta T; Vera M; Sanz I; Junquera ML; Landa MC; Martinez E; Camara MM; Belda J; Bru FJ; Diaz A;
    Euro Surveill; 2014 Nov; 19(47):20971. PubMed ID: 25443036
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Survey of Pretreatment HIV Drug Resistance and Genetic Transmission Network Analysis Among HIV Patients in a High Drug-Use Area of Southwest China.
    Liu L; Dong A; Liao L; Feng Y; Shao Y; Liang S; Ruan Y; Xing H
    Curr HIV Res; 2019; 17(6):441-451. PubMed ID: 31778107
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Prevalence of sexually acquired antiretroviral drug resistance in a community sample of HIV-positive men who have sex with men in New York City.
    Goldsamt LA; Clatts MC; Parker MM; Colon V; Hallack R; Messina MG
    AIDS Patient Care STDS; 2011 May; 25(5):287-93. PubMed ID: 21457055
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Short communication: emerging transmitted HIV type 1 drug resistance mutations among patients prior to start of first-line antiretroviral therapy in middle and low prevalence sites in China.
    Wang X; He C; Xing H; Liao L; Xu X; He J; Liu Y; Ling H; Liang S; Hsi JH; Ruan Y; Shao Y
    AIDS Res Hum Retroviruses; 2012 Dec; 28(12):1637-9. PubMed ID: 22822770
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Evolving patterns of HIV-1 resistance to antiretroviral agents in newly infected individuals.
    Simon V; Vanderhoeven J; Hurley A; Ramratnam B; Louie M; Dawson K; Parkin N; Boden D; Markowitz M
    AIDS; 2002 Jul; 16(11):1511-9. PubMed ID: 12131189
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.